IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published 1 week
Medical Professional
ctDNA Week 3 Indicator
Dr. Sandip Patel discusses the impact of adding chemotherapy in patients progressing on 1L osimertinib. (Video 1/3)
Sandip Patel, MD
Dr. Laura van ‘t Veer reviews ctDNA clearance at week 3 as an early indicator in breast cancer (Video 2/3)
Laura van 't Veer, PhD
Dr. Joshua Richter discusses the MOA of CELMoDs and efficacy of MeziKd (Video 1/3)
Joshua Richter, MD
Dr. Joe Mendez reviews vorasidenib for IDH mutant low-grade gliomas (Video 1/3)
Joe Mendez, MD
Dr. Arnab Basu shares his thoughts on ctDNA-guided approaches and their impact to clinical practice today (Video 3/3)
Arnab Basu, MD
Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)
Laura van 't Veer, PhD